CAL2 Detects CALRETICULIN Mutations in Bone Marrow Biopsies

Share this content:
Monoclonal antibody is a specific, sensitive, rapid, simple, and low-cost method of detecting CALRETICULIN mutations.
Monoclonal antibody is a specific, sensitive, rapid, simple, and low-cost method of detecting CALRETICULIN mutations.

German researchers have developed a monoclonal antibody (CAL2) that when used in immunohistochemical assays is a specific, sensitive, rapid, simple, and low-cost method of detecting CALRETICULIN (CALR) mutations.1

CALR mutations are a major driver in myeloproliferative neoplasms (MPNs) and are mainly associated with primary myelofibrosis (PMF) and essential thrombocytopenia (ET). Previously, they were only detectable by molecular assays, which were overly complicated and had limitatations.

Researchers developed a mouse hybridoma designated as CAL2 that secretes antibodies that selectively stain cells carrying mutated CALR proteins in routinely processed bone marrow paraffin sections.

RELATED: New Insights into the Association Between Renal Cell Carcinoma, Hematologic Malignancies

It was tested on 173 human specimens, including bone marrow samples consisting of myeloid and non-myeloid neoplasms and non-neoplastic samples.

The CAL2 monoclonal antibody was used to stain the MPNs, other bone marrow disease, and normal bone marrow. Results were consisted over repeated stainings. This method was compared with the Sanger sequencing and produced a 100% correlation.

Reference

  1. Stein H, Bob R, Durkip, Erck C, et al. A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies. [published online ahead of print August 14, 2015]. Leukemia. doi: 10.1038/leu.2015.192.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs